Suppliers and packagers for ELMIRON

ELMIRON

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Janssen Pharms	ELMIRON	pentosan polysulfate sodium	CAPSULE;ORAL	020193	NDA	Janssen Pharmaceuticals, Inc.	50458-098-01	100 CAPSULE, GELATIN COATED in 1 BOTTLE (50458-098-01)	1996-09-26

Suppliers for the Pharmaceutical Drug: Elmiron

Last updated: August 2, 2025

Introduction

Elmiron (pentosan polysulfate sodium) is a prescription medication primarily used to treat bladder pain associated with interstitial cystitis (IC), a chronic bladder condition characterized by discomfort and pressure. Approved by the U.S. Food and Drug Administration (FDA) in 1996, Elmiron’s manufacturing, distribution, and supply chain are critical elements affecting patient access, pricing, and market stability. This comprehensive overview examines the key suppliers involved in the production and distribution of Elmiron, exploring manufacturing dynamics, supply chain considerations, regulatory implications, and future supply prospects.

---

Manufacturers of Pentosan Polysulfate Sodium

Main Producing Companies

Elmiron’s active pharmaceutical ingredient (API), pentosan polysulfate sodium (PPS), is manufactured by a limited number of global pharmaceutical and chemical companies with specialized capabilities in producing complex sulfated polysaccharides.

• Eli Lilly and Company
  Eli Lilly originally developed Elmiron, and for an extended period, supplied the drug with API manufacturing facilities based in the United States and Europe. Lilly's manufacturing plants adhered to strict Good Manufacturing Practice (GMP) standards, ensuring product consistency and safety. However, Lilly announced in 2020 its decision to exit the bladder health market, including the phased discontinuation of Elmiron, significantly impacting its supply chain.

• Other API Suppliers
  Following Eli Lilly's exit, reliance on alternative suppliers has increased. Chinese and Indian chemical manufacturers have emerged as suppliers of PPS intermediates or APIs, often producing in GMP-compliant facilities. These manufacturers include Shanghai-based companies and Indian pharmaceutical producers specializing in complex polysaccharides. However, specific company identities and their GMP status are often tightly held or confidential due to regulatory and intellectual property considerations.

Contract Manufacturing Organizations (CMOs)

Given the complex nature of PPS synthesis, pharmaceutical companies often outsource manufacturing to specialized CMOs that possess advanced recombinant or chemical synthesis technologies. These CMOs are responsible for ensuring drug quality, stability, and compliance with international standards.

Implications of Manufacturer Concentration

Eli Lilly’s withdrawal has created a supply vacuum, prompting new entrants—predominantly from Asia—to fill the gap. The global supply chain now relies heavily on these third-party manufacturers, raising concerns about quality control, intellectual property rights, and regulatory harmonization, especially given the critical need for GMP compliance in sterile and injectable products.

---

Distribution and Supply Chain Dynamics

Distribution Channels

Elmiron is distributed through a network of pharmaceutical wholesalers, specialty distributors, and direct pharmacy arrangements. Major wholesale distributors such as Cardinal Health, McKesson, and AmerisourceBergen handle the bulk distribution in the United States, ensuring supply to hospitals, specialty pharmacies, and outpatient clinics.

Logistics and Inventory Management

Given the scarcity created by Eli Lilly’s exit, inventory management has become critical. Supply shortages have occasionally been reported, leading to stockouts and fluctuating prices. Manufacturers and distributors are increasingly prioritizing reliable supply channels and maintaining buffer stocks to mitigate disruptions.

Regulatory Oversight

The FDA’s role in approving manufacturing facilities, monitoring quality, and overseeing importation plays a pivotal role in maintaining supply integrity. Importation of PPS API from approved foreign manufacturers has become more prevalent, necessitating rigorous compliance with U.S. regulations.

---

Regulatory and Patent Considerations

Patent Expiry and Market Competition

Elmiron’s patent protection expired or is close to expiry, allowing generics and alternative suppliers to enter the market. This has intensified competition, leading to the emergence of biosimilar and generic PPS products, which can potentially lower costs but also introduce quality variability.

Regulatory Challenges

Suppliers must navigate complex regulatory pathways, especially for imported APIs. Ensuring compliance with the Drug Supply Chain Security Act (DSCSA) and GMP standards is essential to avoid supply disruptions and legal liabilities.

---

Market Outlook and Future Supply Prospects

Potential for New Entrants

The market for PPS is projected to evolve with new entrants from Asia and possibly European manufacturers seeking to capitalize on unmet demand due to limited current supply. Their success depends on obtaining necessary regulatory approvals and establishing reliable GMP-compliant manufacturing processes.

Sustainability and Supply Chain Resilience

Enhancing supply chain resilience involves diversifying supplier bases, investing in production infrastructure, and establishing strategic partnerships. Verifying supplier GMP certifications, conducting quality audits, and fostering transparency are vital to ensure continuous Elmiron supply.

Emerging Alternatives and Innovations

Research into alternative therapeutics for interstitial cystitis may also influence supply dynamics. If new drugs demonstrate superior efficacy or safety, they could diminish Elmiron demand and impact suppliers' strategic priorities.

---

Key Takeaways

• Eli Lilly was the primary supplier of Elmiron but announced withdrawal from the bladder health market, creating supply constraints.
• The API production for pentosan polysulfate sodium now depends on an emerging network of Asian manufacturers, often through third-party CMOs.
• Supply chain resilience is critical; reliance on foreign manufacturers necessitates diligent quality and regulatory oversight.
• The market for PPS is competitive, with generics and biosimilars gaining prominence; patent expirations are key drivers.
• Regulatory compliance remains a cornerstone of supplier qualification, affecting safety, quality, and uninterrupted availability.

---

FAQs

1. Who are the current suppliers of pentosan polysulfate sodium API for Elmiron?
While Eli Lilly was the longstanding supplier, recent supply shifts involve several Asian-based manufacturers, including Chinese and Indian chemical producers, often supplying via CMOs. Exact company identities are typically confidential due to proprietary and regulatory reasons.

2. Are there generic versions of Elmiron available in the market?
Yes. Following patent expirations and Eli Lilly’s market exit, generic formulations produced by multiple manufacturers have entered the market, increasing availability but raising questions about supply consistency.

3. What challenges do suppliers face in manufacturing PPS?
Complex sulfated polysaccharide synthesis requires rigorous quality control, GMP compliance, and stable supply of raw materials. Variability in raw material quality and maintaining consistent production at scale remain significant challenges.

4. How does Eli Lilly’s market exit affect patient access to Elmiron?
The exit has led to supply shortages, increased prices, and limited access, especially in regions dependent on Eli Lilly’s distribution. Alternative suppliers and generics aim to bridge this gap but face regulatory and quality hurdles.

5. What is the outlook for the future supply of Elmiron?
Supply stability depends on the entry of compliant foreign manufacturers, regulatory approvals, and industry investment in manufacturing capacity. Supply chain diversification and quality assurance are pivotal to ensuring ongoing patient access.

---

Sources

1. U.S. Food and Drug Administration (FDA). "Elmiron (pentosan polysulfate sodium) drug information." FDA.gov.

2. Eli Lilly and Company Press Releases. "Eli Lilly Announces Discontinuation of ELmiron in the U.S." (2020).

3. Market Research Reports on Interstitial Cystitis and PPS Supply Chain Dynamics.

4. Industry analyses on global API manufacturing and outsourcing trends, including reports from PharmSource and IQVIA.

5. Relevant regulatory documents and import/export standards from U.S. FDA and international bodies.